anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiac arrest in the postoperative cardiac surgery patient requires a unique set of management skills that deviates from traditional cardiopulmonary resuscitation and Advanced Cardiovascular Life Support (ACLS). Cardiac Advanced Life Support (CALS) was first proposed in 2005 to address these intricacies. The hallmark of CALS is early chest reopening and internal cardiac massage within 5 minutes of the cardiac arrest in patients unresponsive to basic life support. Since the introduction of CALS, the landscape of cardiac surgery has continued to evolve. Cardiac intensivists encounter more patients who undergo cardiac surgical procedures performed via minimally invasive techniques such as lateral thoracotomy or mini sternotomy, in which an initial bedside sternotomy for cardiac massage is not applicable. Given the heterogeneous nature of the patient population in the cardiothoracic intensive care unit, personnel must expeditiously identify the most appropriate rescue strategy. As such, we have proposed a modified CALS approach to (1) adapt to a newer generation of cardiac surgery patients and (2) incorporate advanced resuscitative techniques. These include rescue-focused cardiac ultrasound to aid in the early identification of underlying pathology and guide resuscitation and early institution of extracorporeal cardiopulmonary resuscitation instead of chest reopening. While these therapies are not immediately available in all cardiac surgery centers, we hope this creates a framework to revise guidelines to include these recommendations to improve outcomes and how cardiac anesthesiologist intensivists' evolving role can aid resuscitation.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects 0.5-1% of the population, and where many patients in spite of modern pharmacological treatment fail to reach remission. This affects physical as well as mental wellbeing and leads to severely reduced quality of life and reduced work capacity, thus yielding high individual as well as societal costs. To optimize treatment, alternatives such as diet should be evaluated as complement to pharmacological treatment. The main goal of the randomized cross-over trial ADIRA (Anti-inflammatory Diet In Rheumatoid Arthritis) is to test the hypothesis that a diet intervention will decrease disease activity and costs and improve quality of life in patients with established RA. In total, 60 RA patients with moderate disease activity will be randomized to receive initially either a portfolio diet based on several food items with suggested anti-inflammatory effects or a control diet (western type), during 2 x 10 wks with a 3 months wash-out between diets. Both groups continue with regular pharmacological treatment. Known food biomarkers will be analyzed to measure intervention compliance. Impact on disease activity (measured by DAS28, a composite score which predicts disability and progression of RA) and quality of life is evaluated after each diet regimen. Metabolomics will be used to evaluate the potential to predict responders to dietary treatment. ADIRA will provide evidence whether dietary treatment of RA leads to more patients reaching remission and improved quality of life and work capacity as well as reduce individual and societal costs. Scientific evidence exists for anti-inflammatory effect by single foods on RA, but no study exists where these foods have been combined to obtain maximum effect and thus have the potential to offer a substantial improvement in patient life quality. Such evidence has been asked for by RA patents as well as by treating physicians.
The term MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries) refers to myocardial infarction cases where coronary arteries exhibit less than 50 % stenosis. MINOCA encompasses a diverse range of pathologies with varying etiologies. Diagnosis involves meeting acute myocardial infarction criteria and excluding other causes (myocarditis, takotsubo syndrome). Clinical features often resemble those of traditional myocardial infarction, but MINOCA patients tend to be younger and more frequently female. Etiological investigations include coronary angiography, intracoronary imaging, and vasomotor function tests. Causes include plaque rupture, coronary dissection, vasospasm, microvascular dysfunction, thromboembolism. Prognosis varies, with some subsets at higher risk. Management involves a tailored approach addressing underlying causes, with emphasis on cardioprotective therapy, risk factor modification, and lifestyle interventions. Further research is needed to refine diagnostic strategies and optimize therapeutic approaches in MINOCA patients.
Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
An example Internet-based system involves a database and search capabilities for connecting patients with healthcare providers, and further enables such providers to reach patients with whom they may not otherwise come into contact. A patient may access the healthcare provider information through a search conducted using a search engine. Alternatively, a patient may access the company website's predetermined web page that provides search capabilities on its database. A patient may research a healthcare provider based on criteria specified by the patient. Information provided to the patient may be in the form of a report or profile, including healthcare provider verified information, information verified by an independent third party, and patient provided information. The patient provided information may be in the form of endorsements from former patients that identify skill areas that are areas of strength for the healthcare providers.
CD19/CD22-Dual-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of Dual-STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 500mg/m2 for 3 days and take a rest for 2 days before infusion. Dual-STAR-T cells will be intravenously infused with a escalated dose of 6E5、1E6、2E6、3E6 cells/kg.
Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
Enhanced recovery after surgery (ERAS) strategy has been used in the patient management of different diseases, but up to now, few effort has been done to evaluate the effectiveness of ERAS in patients perioperative management of cervical spine surgery. As a interdisciplinary cooperation system, either qualitative or quantitative method alone can not completely reflect the function of ERAS. Mixed model research (MMR) is a appropriate method to evaluate a complex system, but it has not been used in ERAS evaluation. This study aims to evaluate the effectiveness of ERAS in the perioperative period of posterior approach of cervical spine operation among patients with CSM using MMR, including the retrospective quantitative part and prospective qualitative part. In the retrospective part, we will collect the data of length of stay, VAS scores, mJOA scores and SF-36 scores to compare the difference between ERAS group and regular group. In the prospective part, we will collect the data from the focus group meetings and personal interviews of patients, to verify that ERAS has the ability to improve the postoperative outcomes, while maintain an equal surgical effect.
Participants in group A will be educate thoroughly about treatment plan which includes routine neuro physical therapy aiming (Gross Motor Function \& Balance) A class will be organized to educate Mothers/ Caregivers through PPT presentation, video and pictures. This class will contain 3 domains (Counseling, Educating, Practicing). Feedback will be taken on daily basis through video recordings. Mothers will take part in treatment session, 45 minutes for 5 days a week for 8 weeks.
BACKGROUND: Underweight is a prevalent condition among older adults in developing countries and poses a substantial burden on health, social, and aged-care systems. In this study, we examined the influence of tobacco use and food insecurity on the risk of being underweight among adults aged 60 or older in India.
METHODS: We used data from the 2017-2018 Longitudinal Aging Study in India. The sample size was 27,902 adults aged 60 years and above. We distinguished between smoking and smokeless tobacco use to examine how they may independently contribute to the outcome, while food insecurity was measured using the four-item version of the Food Insecurity Experience scale. Multivariable logistic regressions were conducted to assess the impact of tobacco use and food insecurity on the outcome. Additionally, we tested interactions between tobacco use and education, as well as between tobacco use and wealth.
RESULTS: The prevalence of underweight was 27% in the study population. Older adults who used smoking tobacco were twice more likely to be underweight than non-users (OR = 2.07, 95% CI = 1.79 to 2.40, p < 0.001), controlling for other confounders. The positive association between smokeless tobacco use and underweight was weaker but still significant (OR = 1.26, 95% CI = 1.11 to 1.42, p < 0.001). Food-insecure older adults were also more likely to be underweight (OR = 1.27, 95% CI = 1.10 to 1.48, p < 0.001). Other risk factors of underweight included males, rural residents, lower socioeconomic status (in terms of education, wealth, and caste), chewing disability, poor self-rated health, chronic lung disease, and tuberculosis. Interestingly, tobacco use moderated the relationship between wealth and underweight, such that smokers are more likely to be underweight as they become more affluent.
CONCLUSIONS: Tobacco use and food insecurity have adverse implications on the nutritional status of the older persons in developing countries such as India. More targeted tobacco cessation measures and active food assistance programs for older adults are warranted to improve the overall health status of the older demographic.
Subjects with PCR negative test \> 5d (\~100 participants). Cohort 3 \& 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
Generalized edema is commonly encountered in everyday clinical practice, usually due to heart, liver and renal disease. On the other hand, edema related to fluid extravasation associated with hypotension, hemoconcentration and hypalbuminemia is a rare clinical disorder. We present a case of a 61-year-old man with 3 subsequent endothelium permeability alteration episodes with increasing severity related to Sars-Cov-2 infection. During the last episode he was admitted to the intensive care unit, a monoclonal gammopathy was diagnosed and acute kidney injury requiring continuous renal replacement therapy developed. Systemic capillary leak syndrome or Cklarkson's disease was diagnosed, and the three phases of the condition were recognized, i.e. the prodromal phase, the acute shock phase and the recovery phase. The patients recovered and his kidney function returned to normal values. Nephrologists should be aware of plasma leakage syndromes being their management, especially fluid infusion, difficult due to the risk of complications such as acute kidney injury, compartment syndrome and neuropathy, rhabdomyolysis, myocardial edema, pericardial-pleural-abdominal effusion, deep vein thrombosis and acute pulmonary edema. Sars-Cov-2 infection appears to have increased the frequency of this rare disease.
FIELD: medicine, pharmaceutics. SUBSTANCE: innovation deals with preparations applied for prophylaxis and treatment of osteoarthroses and other articular lesions accompanied with degenerative-dystrophic alterations of articular and paraarticular tissues. Said composition includes uronic acids, hexosamines, calcium, phosphorus, magnesium, amine nitrogen in the form of free amino acids and oligopeptides. At obtaining pharmaceutical composition one should use osseous material and cartilaginous hydrolyzate to be mixed and dried after isolation. To obtain ingredients of pharmaceutical composition one should apply acid hydrolysis of cartilaginous tissue and decalcination of bony tissue. Said preparation provides possibility to produce compositions under clinico-laboratory conditions according to individual indications. EFFECT: higher efficiency of prophylaxis and therapy. 2 cl
Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
OBJECTIVE: DNA methylation data can be used to derive mitotic indices from complex tissues. Here, we assessed if the DNA methylation-derived mitotic ageing indices are associated with oral squamous cell carcinoma (OSCC) development and recurrence-free survival (RFS).
METHODS: DNA methylation-based mitotic indices (MitoticAge, TNSC and hypoSC) were derived using algorithms "MitoticAge" and "epiTOC2" for the discovery [non-malignant (n = 22), premalignant (n = 22) and OSCC (n = 68) tissues] and validation datasets (GSE87053, GSE136704 and TCGA-HNSCC). Differences in mitotic indices between non-malignant, premalignant and OSCC tissues were assessed. Finally, the association between estimated mitotic indices and RFS was evaluated in OSCCs.
RESULTS: In the discovery and validation datasets, increased mitotic ageing was observed in OSCC compared to non-malignant and premalignant oral tissues. HPV-positive HNSCCs had higher mitotic index TNSC. Mitotic age index hypoSC was associated with RFS in OSCC (p = 0.011, HR 2.61, 95% CI 1.24-5.48).
CONCLUSIONS: DNA methylation-derived mitotic indices are associated with OSCC development and RFS. Thus, DNA methylation-derived mitotic indices may be a valuable research tool to reliably estimate the cumulative number of stem cell divisions in malignant and non-malignant oral tissues. Future research utilizing mitotic indices for predicting clinical outcomes in OSCC is warranted.
Cardiovascular disease is the major cause of death and disability in patients with end-stage renal disease on hemodialysis. It has been hypothesized that ingestion of calcium-based phosphate binders results in net positive calcium balance and vascular calcium deposition. Chertow et al. tested the role of ingested calcium in the progression of cardiovascular calcification in the Treat-To-Goal study (Kidney International 62:245, 2002). They reported that patients treated with calcium-based phosphate binders demonstrated progressive cardiovascular calcification, while patients treated with a calcium-free binder, sevelamer, showed stabilization or improvement in calcification scores. However, the protocol did not prohibit intake of supplemental oral calcium in the sevelamer group, which confounded their ability to accurately test the calcium hypothesis. Moreover, due to the cholesterol sequestering activities of sevelamer, the low-density lipoprotein (LDL) cholesterol was lower among sevelamer-treated patients than the calcium treated patients, resulting in a major imbalance in a cardiovascular risk factor. Lowering LDL level reduces progression of CVC and therefore confounds interpretation of the study. Subsequently, it has been reported in the lay press that patients randomized to sevelamer or calcium-based binders in the Dialysis Clinical Outcomes Revisited (DCOR) study have failed to show a difference in mortality or major secondary endpoints (Suki et al., To be presented American Society of Nephrology November 2005). To circumvent these limitations, the CARE-2 study will test the hypothesis that if LDL levels are lowered to a similar level in calcium acetate and sevelamer-treated patients, there will be no difference in the progression of cardiac calcification. CARE-2 will randomize patients with elevated LDL to calcium acetate or sevelamer. Atorvastatin is added to achieve LDL \< 70 mg/dL in both treatment groups. The primary endpoint is change in cardiac calcification scores, determined by electron beam scanning after 1 year. Secondary endpoints include the ability of calcium acetate and sevelamer to control phosphorus and meet NKF-K/DOQI guidelines.
The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis, which is characterized by comprising, by weight, 10-20 g of radix pseudostellariae, 10-15 g of adenophora tetraphylla, 10-15 g of raw white peony root, 10-15 g of radix ophiopogonis, 10-15 g of dendrobe, 6-9 g of fingered citron, 3-6 g of coptis chinensis, 3-9 g of fructus evodiae, 10-15 g of rhizoma corydalis, 3-5 g of raw liquorice, 10-20 g of concha arcae, 10-15 g of fried rice sprout and 10-15 g of fried malt, and is suitable for stomach-yin deficiency. The invention takes radix pseudostellariae and adenophora stricta as monarch drugs. Radix paeoniae alba, radix ophiopogonis and dendrobium nobile are ministerial drugs. Coptis root, evodia rutaecarpa, corydalis tuber and fingered citron; concha arcae is used as adjuvant drug, and Glycyrrhrizae radix is used as messenger drug to harmonize the effects of the other drugs in the recipe. The compatibility of medicines is precise and appropriate, thereby not only playing the role of each medicine, but also mobilizing the synergistic interaction among medicines. The prescription has the effects of tonifying deficiency without drastic effect, tonifying qi without elevating, promoting the production of body fluid without assisting dampness; has the effects of nourishing yin, invigorating qi, invigorating spleen and eliminating dampness; the ministerial drugs are combined to assist the main effect of the monarch drug; the adjuvant drugs are used together with the liver-soothing and yin-nourishing herbs to avoid the defect of stomach obstruction caused by greasy taste. The effective rate of atrophic gastritis reaches 92.3 percent; the effective rate of improving the mucous membrane under the gastroscope reaches 88.5 percent.
Denmark: usual care offered by the GP or local municipality. The UK: tier 3 weight management services.
The invention discloses an oral ivermectin microemulsion concentrate and a preparation method and application thereof, and belongs to the field of medicine and pharmacy. The oral ivermectin microemulsion concentrate product uses auxiliary materials mainly comprising natural ingredients and pharmaceutical grade auxiliary materials, is high in safety and environment friendly, and overcomes the problems of the existing product environmental pollution. The oral ivermectin microemulsion concentrate has simple preparation process, and is only related to the ordinary mixing process. The oral ivermectin microemulsion concentrate product can spontaneously emulsify by diluting with tap water and other water solution and slight oscillation, and under the optimum conditions, the emulsified average particle size is 0.05 to 0.2 mum. The oral ivermectin microemulsion concentrate product has good liquidity, and may not be hung on the wall, the appearance is single-phase, transparent and clear, and after repeated freezing and thawing, preparation stratification phenomenon may not occur, and preparations emulsification effect may not be affected. The oral ivermectin microemulsion concentrate product is used for controlling livestock gastrointestinal nematodiasis, bovine myiasis, hypoderma lineatum, sheep nasal myiasis, goat scab mite, swine sarcoptic mange and other parasitic insects diseases.
The means is used for the treatment of diseases where the functional of phagocytosis, complement system, interferon, T & B lymphocytes, secretory IgA, pulmonary surfactant are suppressed. It stimulates the natural factors of the immune system by relatively small quantities of bacterial products, alient to human organism. The means is a combination based on bacterial suspension of microorganisms of the species: Streptococcus pneumoniae, Neisseria catdrrhalis, Streptococcus pyogenes, Hemophilus influenzae, Staphylococcus aureus and Klebsiells pneumoniae in quantities from 0.125,109 to 0.625,109 bacterial bodies of every type, from 0.15 to 0.75 mg tocopherol acetatoleosum and from 2 to 10 mg microcapsulated -tocopherol acetate per dose, in the form of gastro- and interstinal-soluble filmtablets with suitable supplementary substances. Together with stabilizers of the bacterial suspension. It is produced by the cultivation of microbial species at specified conditions in a fermenter, killing of the bacterial mass and after a pause - mixing of the individual suspensions. The mixture is stabilized by tocopherol acetatoleosum, it is lyophilized, granulated and microcapsulated -tocopherol acetate is added. There follows tableting and film-coating for the production of gastro- or intestine-soluble filmtablets.
PURPOSE: This study aimed to evaluate the efficacy and clinical outcomes of a one-way fluid-air exchange procedure for the treatment of postvitrectomy diabetic vitreous hemorrhage in patients with proliferative diabetic retinopathy.
METHODS: This retrospective study included 233 patients with proliferative diabetic retinopathy, who underwent vitrectomy. A one-way fluid-air exchange procedure was performed in 24 eyes of 24 (10.30%) patients with persistent vitreous cavity rebleeding after the operation. Preprocedural and postprocedural best-corrected visual acuity values were achieved. Complications occurring during and after the procedure were analyzed.
RESULTS: Significant visual improvement was observed 1 month after the one-way fluid-air exchange procedure (2.62 ± 0.60 LogMAR at baseline vs. 0.85 ± 0.94 LogMAR at postprocedure, p<0.0001). Moreover, 19 (79.17%) eyes needed the procedure once, and 5 (20.83%) eyed had the procedure more than twice. In 3 (12.50%) eyes, reoperation was eventually required because of persistent rebleeding despite several fluid-air exchanges. No complication was observed during the follow-up.
CONCLUSIONS: The one-way fluid-air exchange procedure can be an excellent alternative to re-vitrectomy for patients with proliferative diabetic retinopathy suffering from postvitrectomy diabetic vitreous hemorrhage by removing the hemorrhagic contents directly and achieving fast recovery of visual function without apparent complications.
<P>PROBLEM TO BE SOLVED: To provide an aqueous solution preparation comprising an antibody and having a pH of 6.00-7.00, particularly an aqueous solution preparation keeping the antibody stable even after long-term preservation.  <P>SOLUTION: The aqueous solution preparation comprises a buffering agent, a surfactant, an antioxidant, an isotonic agent and an antibody and has a pH of 6.00-7.00. The surfactant is preferably a polysorbate, more preferably polysorbate 80. The antioxidant is preferably methionine. The isotonic agent is preferably sugar or sorbitol. The concentration of the buffering agent is preferably 10-20 mM. The surfactant is preferably polysorbate 80 in a concentration of 0.5-1.0 mg/mL. The concentration of methionine as the antioxidant is preferably 10-15 mM.  <P>COPYRIGHT: (C)2011,JPO&INPIT